US4021492A
(en)
*
|
1975-03-24 |
1977-05-03 |
Sandoz, Inc. |
Dibromination process
|
SE414305B
(sv)
*
|
1976-08-25 |
1980-07-21 |
Astra Laekemedel Ab |
Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
|
EP0003002B1
(de)
*
|
1977-12-22 |
1984-06-13 |
Ciba-Geigy Ag |
Verwendung von aromatisch-aliphatischen Ketonen als Photoinitiatoren, photopolymerisierbare Systeme enthaltend solche Ketone und neue aromatisch-aliphatische Ketone
|
FR2430933A1
(fr)
*
|
1978-07-13 |
1980-02-08 |
Synthelabo |
Derives de propiophenone et leur application en therapeutique
|
US4347257A
(en)
*
|
1979-10-09 |
1982-08-31 |
Burroughs Wellcome Co. |
Prolactin suppression in mammals
|
FR2486074A1
(fr)
*
|
1979-12-14 |
1982-01-08 |
Lafon Labor |
Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
|
EP0038071B1
(de)
*
|
1980-04-14 |
1984-11-14 |
The Wellcome Foundation Limited |
Radioaktiv markierte und unmarkierte Butylaminopropiophenon-Derivate, ihre Herstellung, aus den unmarkierten Derivaten erzeugte Immunogene und ein Verfahren zur Herstellung der Antisera, durch Immunogen hergestellte Antisera und Verfahren zur Herstellung der Antisera, ein Radioimmunoassayverfahren und eine Reagentiengarnitur zum Gebrauch bei dieser Methode
|
ATE8987T1
(de)
*
|
1981-03-23 |
1984-09-15 |
Laboratoire L. Lafon Societe Anonyme Dite: |
Fluorphenacyl-amin-derivate und ihre therapeutische verwendung.
|
JPS57169450A
(en)
*
|
1981-04-13 |
1982-10-19 |
Lafon Labor |
Fluorophenacyl-amine derivative and application to remedy
|
US4393078A
(en)
*
|
1982-03-15 |
1983-07-12 |
Burroughs Wellcome Co. |
Bupropion and ethanol
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
US4507323A
(en)
*
|
1984-07-25 |
1985-03-26 |
Burroughs Wellcome Co. |
Treatment of psychosexual dysfunctions
|
US5236922A
(en)
*
|
1984-08-20 |
1993-08-17 |
Laboratoire L. Lafon |
Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives
|
FR2569185B1
(fr)
*
|
1984-08-20 |
1986-09-05 |
Lafon Labor |
Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
|
FR2569184A1
(fr)
*
|
1984-08-20 |
1986-02-21 |
Lafon Labor |
Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
|
GB9217295D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5358970A
(en)
*
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
WO1995022324A1
(en)
*
|
1994-02-18 |
1995-08-24 |
Walter Pinsker |
Treatment of migraine headaches and formulations
|
US5753712A
(en)
*
|
1994-02-18 |
1998-05-19 |
Pinsker; Walter |
Treatment of migraine headaches and formulations
|
US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
*
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
JP2002501891A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(+)−ビュープロピオンの医薬用途
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
MXPA04011203A
(es)
|
2002-05-17 |
2005-07-14 |
Univ Duke |
Metodo para tratar la obesidad.
|
KR101228376B1
(ko)
*
|
2002-07-18 |
2013-01-31 |
사이토스 바이오테크놀로지 아게 |
합텐-캐리어 컨쥬게이트 및 그의 용도
|
AU2002337634A1
(en)
*
|
2002-09-10 |
2004-04-30 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Process for the preparation of bupropion hydrochloride
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
ITMI20030762A1
(it)
*
|
2003-04-11 |
2004-10-12 |
Erregierre Spa |
Processo di cristallizzazione del bupropione cloridrato.
|
DK2316456T3
(en)
*
|
2003-04-29 |
2017-09-11 |
Orexigen Therapeutics Inc |
Compositions for affecting weight loss comprising an opioid antagonist and bupropion
|
EP2112920B1
(de)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
EP2343073A3
(de)
|
2003-12-11 |
2011-10-12 |
Sepracor Inc. |
Kombination eines Beruhigungsmittels und eines Neurotransmittermodulators und Verfahren zur Verbesserung der Schlafqualität und Behandlung von Depressionen
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
EP1734955A2
(de)
|
2004-01-13 |
2006-12-27 |
Duke University |
Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
|
WO2005107806A1
(en)
*
|
2004-04-21 |
2005-11-17 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP2474308A1
(de)
*
|
2005-06-27 |
2012-07-11 |
Valeant International (Barbados) SRL |
Pharmazeutische Formulierungen enthaltend Bupropionhydrobromid
|
SG163588A1
(en)
|
2005-07-08 |
2010-08-30 |
Braincells Inc |
Methods for identifying agents and conditions that modulate neurogenesis
|
EP2258358A3
(de)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
EP2275095A3
(de)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenese durch modulation des Muscarinrezeptors
|
JP2009511607A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
|
KR20080080094A
(ko)
*
|
2005-10-14 |
2008-09-02 |
하. 룬트벡 아크티에 셀스카브 |
에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス,インコーポレイティド |
神経発生のgaba受容体媒介調節
|
ES2402522T3
(es)
|
2005-11-22 |
2013-05-06 |
Orexigen Therapeutics, Inc. |
Composiciones y procedimientos para aumentar la sensibilidad a la insulina
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US7763612B2
(en)
*
|
2006-01-03 |
2010-07-27 |
Algebra, Inc. |
Therapeutic amine-arylsulfonamide conjugate compounds
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US20080044462A1
(en)
*
|
2006-04-06 |
2008-02-21 |
Collegium Pharmaceutical, Inc. Delaware |
Stabilized transdermal bupropion preparations
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
KR20170077291A
(ko)
|
2006-11-09 |
2017-07-05 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
KR101735466B1
(ko)
|
2006-11-09 |
2017-05-15 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
US20090023744A1
(en)
*
|
2007-06-18 |
2009-01-22 |
The General Hospital Corporation |
Combination therapy for depression
|
CN100560563C
(zh)
*
|
2007-07-06 |
2009-11-18 |
浙江普洛医药科技有限公司 |
盐酸安非他酮的合成方法
|
US20090076161A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bupropion
|
US20090148541A1
(en)
*
|
2007-10-16 |
2009-06-11 |
Duke University |
Compositions and methods for the treatment of seborrhea
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
WO2010004386A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Glenmark Generics Limited |
Amorphous bupropion hydrobromide and preparation thereof
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CA2758774C
(en)
|
2009-04-15 |
2015-02-03 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
CN102724878A
(zh)
|
2010-01-11 |
2012-10-10 |
奥雷西根治疗公司 |
在重度抑郁症患者中提供体重减轻疗法的方法
|
LT3730132T
(lt)
|
2012-06-06 |
2022-08-25 |
Nalpropion Pharmaceuticals Llc |
Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
|
US11426370B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9707191B2
(en)
|
2013-11-05 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US9474731B1
(en)
|
2013-11-05 |
2016-10-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457023B1
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11571399B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10864209B2
(en)
|
2013-11-05 |
2020-12-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10080727B2
(en)
|
2013-11-05 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10940124B2
(en)
|
2019-01-07 |
2021-03-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11129826B2
(en)
|
2013-11-05 |
2021-09-28 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US10105327B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
|
US11541021B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11571417B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966941B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llp |
Bupropion as a modulator of drug activity
|
US11576909B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11234946B2
(en)
|
2013-11-05 |
2022-02-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9968568B2
(en)
|
2013-11-05 |
2018-05-15 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11147808B2
(en)
|
2013-11-05 |
2021-10-19 |
Antecip Bioventures Ii Llc |
Method of decreasing the fluctuation index of dextromethorphan
|
US11285146B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10772850B2
(en)
|
2013-11-05 |
2020-09-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11007189B2
(en)
|
2013-11-05 |
2021-05-18 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11590124B2
(en)
|
2013-11-05 |
2023-02-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11020389B2
(en)
|
2013-11-05 |
2021-06-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894046B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10780064B2
(en)
|
2019-01-07 |
2020-09-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874665B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20160324807A1
(en)
|
2013-11-05 |
2016-11-10 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874664B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10898453B2
(en)
|
2013-11-05 |
2021-01-26 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273134B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11478468B2
(en)
|
2013-11-05 |
2022-10-25 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894047B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11090300B2
(en)
|
2013-11-05 |
2021-08-17 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966974B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253491B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10786469B2
(en)
|
2013-11-05 |
2020-09-29 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11185515B2
(en)
|
2013-11-05 |
2021-11-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11596627B2
(en)
|
2013-11-05 |
2023-03-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10881657B2
(en)
|
2013-11-05 |
2021-01-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11382874B2
(en)
|
2013-11-05 |
2022-07-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11534414B2
(en)
|
2013-11-05 |
2022-12-27 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11291638B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966942B2
(en)
|
2019-01-07 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11344544B2
(en)
|
2013-11-05 |
2022-05-31 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10512643B2
(en)
|
2013-11-05 |
2019-12-24 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11096937B2
(en)
|
2013-11-05 |
2021-08-24 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9763932B2
(en)
|
2013-11-05 |
2017-09-19 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11524007B2
(en)
|
2013-11-05 |
2022-12-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9408815B2
(en)
|
2013-11-05 |
2016-08-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10813924B2
(en)
|
2018-03-20 |
2020-10-27 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11298351B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10980800B2
(en)
|
2013-11-05 |
2021-04-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11191739B2
(en)
|
2013-11-05 |
2021-12-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11357744B2
(en)
|
2013-11-05 |
2022-06-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9700528B2
(en)
|
2013-11-05 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US20160361305A1
(en)
|
2013-11-05 |
2016-12-15 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US11433067B2
(en)
|
2013-11-05 |
2022-09-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576877B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as modulator of drug activity
|
US10105361B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US20220233470A1
(en)
|
2013-11-05 |
2022-07-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11517543B2
(en)
|
2013-11-05 |
2022-12-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11364233B2
(en)
|
2013-11-05 |
2022-06-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10799497B2
(en)
|
2013-11-05 |
2020-10-13 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US11298352B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426401B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10933034B2
(en)
|
2013-11-05 |
2021-03-02 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9402843B2
(en)
|
2013-11-05 |
2016-08-02 |
Antecip Bioventures Ii Llc |
Compositions and methods of using threohydroxybupropion for therapeutic purposes
|
US11123343B2
(en)
|
2013-11-05 |
2021-09-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11141416B2
(en)
|
2013-11-05 |
2021-10-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253492B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11497721B2
(en)
|
2013-11-05 |
2022-11-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617728B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10945973B2
(en)
|
2013-11-05 |
2021-03-16 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11541048B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9198905B2
(en)
|
2013-11-05 |
2015-12-01 |
Antecip Bioventures Ii Llc |
Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
|
US11065248B2
(en)
|
2013-11-05 |
2021-07-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273133B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123344B2
(en)
|
2013-11-05 |
2021-09-21 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US11439636B1
(en)
|
2013-11-05 |
2022-09-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11291665B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11419867B2
(en)
|
2013-11-05 |
2022-08-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9861595B2
(en)
|
2013-11-05 |
2018-01-09 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11510918B2
(en)
|
2013-11-05 |
2022-11-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874663B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617747B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11207281B2
(en)
|
2013-11-05 |
2021-12-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285118B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9867819B2
(en)
|
2013-11-05 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11213521B2
(en)
|
2013-11-05 |
2022-01-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457025B2
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US20200338022A1
(en)
|
2019-01-07 |
2020-10-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11229640B2
(en)
|
2013-11-05 |
2022-01-25 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US11058648B2
(en)
|
2013-11-05 |
2021-07-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10688066B2
(en)
|
2018-03-20 |
2020-06-23 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11311534B2
(en)
|
2013-11-05 |
2022-04-26 |
Antecip Bio Ventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11197839B2
(en)
|
2013-11-05 |
2021-12-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
WO2015095713A1
(en)
|
2013-12-20 |
2015-06-25 |
Deuterx, Llc |
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
|
CN106699527A
(zh)
*
|
2016-12-07 |
2017-05-24 |
三峡大学 |
一种间氯苯丙酮的合成方法
|
US10925842B2
(en)
|
2019-01-07 |
2021-02-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|